Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Daiichi Sankyo
Fish and Richardson
Chubb
Moodys
Mallinckrodt
Citi
Merck
QuintilesIMS

Generated: June 24, 2018

DrugPatentWatch Database Preview

CAPRELSA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Caprelsa patents expire, and when can generic versions of Caprelsa launch?

Caprelsa is a drug marketed by Genzyme Corp and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and thirty-seven patent family members in forty-two countries.

The generic ingredient in CAPRELSA is vandetanib. Two suppliers are listed for this compound. Additional details are available on the vandetanib profile page.
Summary for CAPRELSA
Drug patent expirations by year for CAPRELSA
Synonyms for CAPRELSA
(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine
2ivu
338992-00-0
4-(4-Bromo-2-fluoroanilino)-6-methoxy- 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxyquinazoline
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazoline
4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE
4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-
443913-73-3
68541-EP2298768A1
68541-EP2308855A1
913V733
A25648
AB0008635
AB01273969_04
AB01273969-01
AB01273969-02
AB1008463
ABP000873
AC-5251
AC1MIWRU
AJ-45811
AK106976
AKOS015902350
AN-3469
ANW-61824
AOB87780
AS-11067
AZD-6474
BC224441
BCPP000023
BDBM21
C22H24BrFN4O2
Caprelsa (TN)
CAS-443913-73-3
CH 331
CH-331
CHEBI:49960
CHEMBL24828
cid_3081361
CS-0130
CTK8B9016
D06407
D0G6QF
DB05294
DMPC Cyclic Urea 1
DSSTox_CID_26681
DSSTox_GSID_46681
DSSTox_RID_81816
DTXSID1046681
EN002713
EX-A422
F9995-0087
FT-0656736
GNF-PF-2188
GTPL5717
HE069787
HE343618
HMS3244K03
HMS3244K04
HMS3244L03
HMS3654E11
HSDB 8198
HY-10260
I14-1942
KB-34269
Kinome_3316
LS-184394
MCULE-4705827953
MFCD07772346
MLS006011672
MolPort-005-942-399
N-(4-bromo-2-fluoro-phenyl)-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
NCGC00167513-01
NCGC00167513-02
NCGC00167513-03
NCGC00167513-04
NSC-744325
NSC-760766
NSC744325
NSC760766
PubChem22460
QCR-37
Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-
RS0036
RT-016214
s1046
SC-23330
SCHEMBL9044
SMR002530472
SR-00000000462
SR-00000000462-2
ST2407381
SYN1090
Tox21_112511
Tox21_112511_1
UHTHHESEBZOYNR-UHFFFAOYSA-N
UNII-YO460OQ37K
V-9402
Vandetanib
Vandetanib (JAN/INN)
Vandetanib (JAN/USAN/INN)
Vandetanib (Pan-TK inhibitor)
vandetanib (zd6474)
Vandetanib [INN]
Vandetanib [USAN:INN:BAN:JAN]
Vandetanib, Zactima, ZD6474
Vandetanib;7-((4-aminocyclohexyl)methoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine
Vandetanib(Zactima),ZD6474/
Vandetinib
W-5356
YO460OQ37K
Zactima
Zactima, ZD6474
ZD 6474
ZD-64
ZD-6474
ZD6474
ZINC53683345

US Patents and Regulatory Information for CAPRELSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for CAPRELSA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for CAPRELSA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,673,803 Quinazoline derivatives and pharmaceutical compositions containing them ➤ Try a Free Trial
9,040,548 Quinazoline derivatives as VEGF inhibitors ➤ Try a Free Trial
6,897,210 Quinazoline derivatives and pharmaceutical compositions containing them ➤ Try a Free Trial
6,414,148 Quinazoline derivatives and pharmaceutical compositions containing them ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for CAPRELSA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2012000057 Germany ➤ Try a Free Trial PRODUCT NAME: VANDETANIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
9 Finland ➤ Try a Free Trial
0543 Netherlands ➤ Try a Free Trial PRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
1244647/01 Switzerland ➤ Try a Free Trial FORMER OWNER: ASTRAZENECA AB, SE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Cantor Fitzgerald
Federal Trade Commission
Cipla
Medtronic
US Army
QuintilesIMS
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.